Baillie Gifford & Co. Increases Stock Position in Axon Enterprise, Inc $AXON

Key Points

• Baillie Gifford boosted its stake in Axon by 1,198.7% in Q4 to 1,642,578 shares, now owning about 2.08% of the company (worth ~$932.9M) and making AXON its 26th-largest holding.
• Analysts carry a consensus rating of Moderate Buy with a consensus target of $755.88, and several firms have recently set high price targets or raised ratings, though views remain mixed.
• Axon recently beat quarterly estimates (EPS $2.15 vs $1.60; revenue $796.7M vs $755.3M) but trades at a steep valuation (PE ~227.6) amid recent volatility and notable insider selling (~13,855 shares, ~$7.11M over 90 days).

Baillie Gifford & Co. boosted its stake in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 1,198.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,642,578 shares of the biotechnology company's stock after buying an additional 1,516,099 shares during the quarter. Axon Enterprise accounts for about 0.8% of Baillie Gifford & Co.'s holdings, making the stock its 26th biggest holding. Baillie Gifford & Co. owned approximately 2.08% of Axon Enterprise worth $932,869,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also made changes to their positions in the business. Vanguard Group Inc. lifted its position in shares of Axon Enterprise by 4.2% during the third quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company's stock worth $6,684,217,000 after purchasing an additional 376,904 shares in the last quarter. Jennison Associates LLC lifted its position in shares of Axon Enterprise by 53.8% during the third quarter. Jennison Associates LLC now owns 943,944 shares of the biotechnology company's stock worth $677,412,000 after purchasing an additional 330,213 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its position in shares of Axon Enterprise by 23.0% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 838,289 shares of the biotechnology company's stock worth $476,089,000 after purchasing an additional 156,647 shares in the last quarter. Northern Trust Corp lifted its position in shares of Axon Enterprise by 1.6% during the third quarter. Northern Trust Corp now owns 743,926 shares of the biotechnology company's stock worth $533,871,000 after purchasing an additional 11,726 shares in the last quarter. Finally, Legal & General Group Plc lifted its position in shares of Axon Enterprise by 3.1% during the third quarter. Legal & General Group Plc now owns 421,114 shares of the biotechnology company's stock worth $302,208,000 after purchasing an additional 12,736 shares in the last quarter. Institutional investors and hedge funds own 79.08% of the company's stock.

Analyst Ratings Changes

AXON has been the topic of several analyst reports. Northcoast Research raised shares of Axon Enterprise from a "neutral" rating to a "buy" rating and set a $742.00 target price on the stock in a report on Tuesday, January 6th. Piper Sandler reduced their target price on shares of Axon Enterprise from $753.00 to $690.00 and set an "overweight" rating on the stock in a report on Wednesday, February 25th. Morgan Stanley reaffirmed an "overweight" rating on shares of Axon Enterprise in a report on Wednesday. Robert W. Baird set a $800.00 target price on shares of Axon Enterprise in a report on Wednesday, February 25th. Finally, William Blair reissued an "outperform" rating on shares of Axon Enterprise in a report on Tuesday, February 3rd. Sixteen analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $755.88.

Insider Buying and Selling

In other Axon Enterprise news, insider Isaiah Fields sold 2,000 shares of the business's stock in a transaction on Friday, February 27th. The shares were sold at an average price of $535.01, for a total transaction of $1,070,020.00. Following the sale, the insider directly owned 55,588 shares in the company, valued at approximately $29,740,135.88. The trade was a 3.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Erika Nardini sold 198 shares of the business's stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $506.58, for a total transaction of $100,302.84. Following the sale, the director owned 1,946 shares in the company, valued at $985,804.68. The trade was a 9.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 13,855 shares of company stock worth $7,109,828 in the last ninety days. Insiders own 5.70% of the company's stock.

Trending Headlines about Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Connected Devices momentum — Reports note strong demand for TASER 10 units, body cameras and counter‑drone tech, driving growth in Axon’s Connected Devices segment and suggesting upside to hardware and accessory revenue. Axon's Connected Devices Strength Holds Firm
• Positive Sentiment: New AI product push — Axon unveiled three AI tools aimed at tackling public‑safety data overload, which could boost subscription/software revenue and make its hardware more sticky to agency customers. Product innovation is being cited as a catalyst for longer‑term recurring revenue growth. Axon tackles public safety’s data overload with three new AI tools
• Positive Sentiment: Conference/analyst optimism lifted shares earlier — Coverage noted a rebound after Axon’s annual conference and AI product messaging, indicating some analysts view recent innovation as supportive of the growth story. Axon Enterprise stock rises 4% on analyst optimism
• Neutral Sentiment: Analyst views are mixed — Coverage highlights conflicting analyst sentiments on Axon (some bullish on devices/software, others cautious), contributing to short‑term uncertainty in the stock. Analysts Have Conflicting Sentiments on These Industrial Goods Companies
• Negative Sentiment: Sharp recent sell‑off and volatility — Reports show a large one‑day decline in early April, reflecting profit‑taking and heightened sensitivity to guidance/valuation; that pullback is pressuring the stock despite the product and demand narrative. Axon Enterprise (AXON) Stock Drops Despite Market Gains
• Negative Sentiment: High valuation and technical weakness — Axon still trades at a rich P/E and sits well below its 50‑ and 200‑day moving averages, which increases downside risk if execution or guidance disappoints. Axon Enterprise (AXON) Stock Drops Despite Market Gains

Axon Enterprise Stock Performance

Shares of AXON opened at $345.94 on Monday. The company has a current ratio of 2.53, a quick ratio of 2.29 and a debt-to-equity ratio of 0.53. The firm has a market cap of $27.81 billion, a PE ratio of 227.59, a price-to-earnings-growth ratio of 7.38 and a beta of 1.61. The company's 50 day simple moving average is $464.41 and its 200-day simple moving average is $564.42. Axon Enterprise, Inc has a 12-month low of $339.01 and a 12-month high of $885.91.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.60 by $0.55. The business had revenue of $796.72 million for the quarter, compared to analyst estimates of $755.29 million. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The company's revenue for the quarter was up 38.5% compared to the same quarter last year. During the same period last year, the firm posted $2.08 earnings per share. As a group, equities analysts predict that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company's hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.

Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc (NASDAQ:AXON - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.